Ophthalmos Research team has discovered a novel therapy for vision improvement in patients with Stargardt disease. It is one of the most common forms of macular dystrophy and to date no treatment has provided evidence of disease regression. The published paper shows how fatty acids reduced the accumulation of lipofuscin granules and A2E levels and …
The Research team at Ophthalmos Institute has confirmed that Omega-3 fatty acids can protect the optic nerve in glaucoma. ‘Glaucoma is the second leading cause of irreversible blindness, and affects 80 million people worldwide. Several risk factors, especially age and elevated intraocular pressure, play crucial roles in glaucoma development . However, the exact relationship between …
Ophthalmos Research Team have demonstrated that omega 3 fatty acids when used at the right dosage (by testing the blood AA/EPA ratio) could be beneficial in patients with Age Related Macular Degeneration and perhaps other ocular pathologies which involve photoreceptor damage. The benefits will have a positive impact on the quality of life of patients …
Ophthalmos Research team in collaboration with the research team of Professor Tsai from Tzui Chi University, Taiwan have demonstrated for the first time that omega 3 polyunsaturated fatty acids have neuroprotective effects on ischemic optic neuropathies. ‘This is of clinical significance as there is no treatment for ischemic optic neuropathies’ said Dr Tassos Georgiou the …
Age related Macular Degeneration is the leading cause of blindness over the age of 40 years old and Mauclar Dystrophy is the leading cause of blindness under the age of 40 years old.Ophthalmos publishes the results of its patented treatment to alleviate blindness See link: https://www.ncbi.nlm.nih.gov/pubmed/27125064
Ophthalmos has a patented therapy of moderate to severe dry eyes using omega 3 therapy. ‘Omega 3 is beneficial for dry eyes when given at the correct dose and ratio of EPA to DHA. This is simply decided by using a blood test to measure the ratio of AA to EPA’ said Dr Tassos Georgiou, …
AMD is the leading cause of visual impairment and blindness in people over the age of 50 years. The number of people with this disease is estimated at 200 million worldwide and this number is expected to increase in 20 years by 50 %.. In 2010 there was a direct healthcare systems expenditure of $255 …
Ophthalmos Research Team discuss the role of EPA fatty acids and its therapeutic effects on Dry Age Related Macular Degeneration patients. Dr Tassos Georgiou who is the innovator of the therapy says that the innovative treatment discovered by Ophthalmos Research and Educational Institute will improve the quality of life and reduce the disease burden for …
Ophthalmos Research Team is committed to researching and developing innovative potential therapeutic solutions for eye diseases. Following our initial encouraging results of the first clinical observations in patients with ischaemic Optic neuropathy, Ophthalmos is collaborating with Dr Tsai’s Research Team at the Institute of Medical Sciences at Tzu Chi Iniversity, Taiwan. We have shown for …
